Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 305

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

Open access
Kudo, Masatoshi, Ueshima, Kazuomi, Yokosuka, Osamu, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka, Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Akazawa, Kohei, Yoshimura, Ken-ichi, Johnson, Philip, Arai, Yasuaki, Kudo, Masatoshi, Ueshima, Kazuomi, Yokosuka, Osamu, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka, Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Akazawa, Kohei, Yoshimura, Ken-ichi, Johnson, Philip, Arai, Yasuaki · 2018 · The Lancet Gastroenterology & Hepatology

Abstract

BACKGROUND Hepatic arterial infusion chemotherapy plus sorafenib in phase 2 trials has shown favourable tumour control and a manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma. However, no randomised phase 3 trial has tested the combination of sorafenib with continuous arterial infusion chemotherapy. We aimed to compare continuous hepatic arterial infusion chemotherapy plus sorafenib with sorafenib alone in patients with advanced, unresectable hepatocellular carcinoma. METHODS We did an open-label, randomised, phase 3 trial (SILIUS) at 31 sites in Japan. Eligible patients were aged 20 years or older, with advanced hepatocellular carcinoma not suitable for resection, local ablation, or transarterial chemoembolisation; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Child-Pugh score 7 or lower; and adequate bone marrow, liver, and renal function. Patients were randomly assigned (1:1) via an interactive web response system with a computer-generated sequence to receive 400 mg sorafenib orally twice daily or 400 mg sorafenib orally twice daily plus hepatic arterial infusion chemotherapy (cisplatin 20 mg/m2 on days 1 and 8 and fluorouracil 330 mg/m2 continuously on days 1-5 and 8-12 of every 28-day cycle via an implanted catheter system). The primary endpoint was overall survival. The primary efficacy analysis comprised all randomised patients (the intention-to-treat population), and the safety analysis comprised all randomised patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01214343. FINDINGS Between Nov 4, 2010, and June 10, 2014, 206 patients were randomly assigned (103 to the sorafenib group, 103 to the sorafenib plus hepatic arterial infusion chemotherapy group). One patient in the sorafenib plus hepatic arterial infusion chemotherapy group withdrew after randomisation. Median overall survival was similar in the sorafenib plus hepatic arterial infusion chemotherapy (n=102) and sorafenib monotherapy (n=103) groups (11·8 months [95% CI 9·1-14·5] vs 11·5 months [8·2-14·8]; hazard ratio 1·009 [95% CI 0·743-1·371]; p=0·955). Grade 3-4 adverse events that were more frequent in the sorafenib plus hepatic arterial infusion chemotherapy group than in the sorafenib monotherapy group included anaemia (15 [17%] of 88 vs six [6%] of 102), neutropenia (15 [17%] vs one [1%]), thrombocytopenia (30 [34%] vs 12 [12%]), and anorexia (12 [14%] vs six [6%]). INTERPRETATION Addition of hepatic arterial infusion chemotherapy to sorafenib did not significantly improve overall survival in patients with advanced hepatocellular carcinoma. FUNDING Japanese Ministry of Health, Labour and Welfare.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(18)30078-5

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 305

Metadata

Authors
Kudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., Aikata, H., Nagano, H., Hatano, E., Sasaki, Y., Hino, K., Kumada, T., Yamamoto, K., Imai, Y., Iwadou, S., Ogawa, C., Okusaka, T., Kanai, F., Akazawa, K., Yoshimura, K.-I., Johnson, P., Arai, Y., Kudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., Aikata, H., Nagano, H., Hatano, E., Sasaki, Y., Hino, K., Kumada, T., Yamamoto, K., Imai, Y., Iwadou, S., Ogawa, C., Okusaka, T., Kanai, F., Akazawa, K., Yoshimura, K.-I., Johnson, P., & Arai, Y.
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2018-06
Volume
3
Issue
6
Pages
424-432
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W2795708663
Cited by
305
References
16
FWCI
18.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2468-1253(18)30078-5
The paper
Kudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., Aikata, H., Nagano, H., Hatano, E., Sasaki, Y., Hino, K., Kumada, T., Yamamoto, K., Imai, Y., Iwadou, S., Ogawa, C., Okusaka, T., Kanai, F., Akazawa, K., . . . Arai, Y. (2018). Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(18)30078-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.